Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TriPath Imaging, Inc.

This article was originally published in The Gray Sheet

Executive Summary

PMA supplement is submitted to FDA covering use of the AutoPap automated primary Pap smear slide screening system with cytology samples prepared using the Prep automated, liquid-based Pap smear sample preparation system. TriPath is the new name for the recent combination of Prep system developer AutoCyte and AutoPap maker NeoPath under a June merger completed Oct. 1 (1"The Gray Sheet" June 14, p. 15). The Prep system was approved June 17 to replace conventional Pap smear preparation in primary screening for cervical cancer but not specifically for use with AutoPap, which was approved for initial screening of conventional slides in May 1998

You may also be interested in...



AutoCyte's Neopath Acquisition Combines Automated Cytology Offerings

AutoCyte is hoping that its acquisition of NeoPath, a stock-swap transaction valued at over $100 mil., will result in a 50% share of the U.S. Pap smear market.

EU Plans IP Law Shake-Up

European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.

Molecular Dx Company Biocartis ‘At Inflection Point’ As It Eyes Infectious Disease Market

Belgian developer of cancer diagnostics is building an infectious disease portfolio on the back of its new SARS-CoV-2 test and collaborations with Immunexpress and Endpoint Health.

UsernamePublicRestriction

Register

OM004559

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel